Food and Drug Administration Commissioner Marty Makary announced on Monday that his agency is deregulating hormone replacement therapies for menopause patients by calling for manufacturers to remove black box warnings from their products.

Black box warnings are the highest level of caution that the FDA requires for certain potentially dangerous products. Makary, in an opinion piece in the Wall Street Journal on Monday , cited several studies touting the benefits of hormone replacement therapy and demonstrating a lack of correlation between HRT and dangerous outcomes such as breast cancer.

Recommended Stories

Trump says Obamacare funds should go ‘directly’ to Americans in call for Democrats to open government

MAHA skeptical of Trump plan to curb obesity with cheap Ozempic

Texas

See Full Page